Technical Analysis for SESN - Sesen Bio, Inc.

Grade Last Price % Change Price Change
grade F 1.14 4.59% 0.05
SESN closed up 4.59 percent on Friday, September 20, 2019, on 51 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical SESN trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
20 DMA Resistance Bearish 4.59%
Bollinger Band Squeeze Range Contraction 4.59%
Fell Below 20 DMA Bearish 3.64%
Narrow Range Bar Range Contraction 3.64%
NR7 Range Contraction 3.64%
Fell Below 50 DMA Bearish 1.79%
20 DMA Support Bullish 1.79%
Crossed Above 50 DMA Bullish -3.80%

Older signals for SESN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Medicine Cancer Oncology Solid Tumors Monoclonal Antibodies Astrazeneca Bladder Cancer Its Its Products Squamous Cell Carcinoma
Is SESN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.6
52 Week Low 0.66
Average Volume 1,058,852
200-Day Moving Average 1.1964
50-Day Moving Average 1.1534
20-Day Moving Average 1.105
10-Day Moving Average 1.11
Average True Range 0.0598
ADX 9.79
+DI 19.6416
-DI 17.5627
Chandelier Exit (Long, 3 ATRs ) 1.0706
Chandelier Exit (Short, 3 ATRs ) 1.1994
Upper Bollinger Band 1.1688
Lower Bollinger Band 1.0412
Percent B (%b) 0.77
BandWidth 11.547511
MACD Line -0.0143
MACD Signal Line -0.0235
MACD Histogram 0.0092
Fundamentals Value
Market Cap 17.54 Million
Num Shares 15.4 Million
EPS 0.11
Price-to-Earnings (P/E) Ratio 10.36
Price-to-Sales 0.56
Price-to-Book 1.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.22
Resistance 3 (R3) 1.21 1.17 1.20
Resistance 2 (R2) 1.17 1.15 1.18 1.20
Resistance 1 (R1) 1.16 1.14 1.17 1.17 1.19
Pivot Point 1.12 1.12 1.13 1.13 1.12
Support 1 (S1) 1.11 1.10 1.12 1.12 1.09
Support 2 (S2) 1.07 1.09 1.08 1.08
Support 3 (S3) 1.06 1.07 1.08
Support 4 (S4) 1.07